Generalised Anxiety Disorder
Tweet
Other Drugs using in Generalized Anxiety Disorder
The development of partial agonists at the GABA/BDZ receptor complex opens up the possibility of BDZ-like compounds that are effective anxiolytics, but less likely to produce sedation, withdrawal, and memory impairment.
Partial BDZ agonists have been developed, the most comprehensively studied being abecarnil.
Abecarnil displays affinity for BDZ receptors and shows promising anxiolytic effects in initial clinical studies.
Although the data are encouraging, the question remains whether, at well-tolerated doses that are unlikely to produce significant withdrawal, the drug is clinically adequate in GAD